Clinical applications of interferon-γ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation: a pilot proof-of-concept study
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated the proposed clinical application of the combined interpretation of host factors and viral factors in two different cytomegalovirus (CMV) co-infection models. Methods: We prospectively enrolled all human immunodeficiency virus non-infected patients with confirmed Pneumocystitis jirovecii pneumonia (PCP) and those with suspected gastrointestinal CMV disease in a tertiary hospital. All patients underwent CMV interferon-γ releasing assay (IGRA) for CMV (T-track CMV, Lophius Biosciences). We created the 2-axis model with the CMV IGRA results as the x-axis and the results for CMV virus replication as the y-axis, and hypothesized that cases falling in the left upper quadrant (high viral load and low CMVspecific immunity) of the model would be true CMV infections. The CMV IGRA results were concealed from the attending physicians. Results: Of 39 patients with PCP, four (10%) were classified as combined CMV pneumonia, 13 (33%) as bystander activation, and the remaining 22 (56%) as no CMV infection. The data for all four patients with PCP and CMV pneumonia fell in the left upper quadrant of the 2-axis model. Of 24 patients with suspected gastrointestinal CMV disease, 12 (50%) were classified as gastrointestinal CMV disease and the remaining 12 (50%) as bystander activation with no gastrointestinal CMV disease. The data for 11 of the 12 patients (92%) with gastrointestinal CMV disease were located in the left upper quadrant of the 2-axis model. Conclusions: Cases yielding low CMV IGRA results and high CMV viral replication appear to be true CMV infections. Further studies with large number of cases in different types of CMV disease should be proposed.
Abstract
Background/Aims: We evaluated the proposed clinical application of the combined interpretation of host factors and viral factors in two different cytomegalovirus (CMV) co-infection models. Methods: We prospectively enrolled all human immunodeficiency virus non-infected patients with confirmed Pneumocystitis jirovecii pneumonia (PCP) and those with suspected gastrointestinal CMV disease in a tertiary hospital. All patients underwent CMV interferon-γ releasing assay (IGRA) for CMV (T-track CMV, Lophius Biosciences). We created the 2-axis model with the CMV IGRA results as the x-axis and the results for CMV virus replication as the y-axis, and hypothesized that cases falling in the left upper quadrant (high viral load and low CMVspecific immunity) of the model would be true CMV infections. The CMV IGRA results were concealed from the attending physicians. Results: Of 39 patients with PCP, four (10%) were classified as combined CMV pneumonia, 13 (33%) as bystander activation, and the remaining 22 (56%) as no CMV infection. The data for all four patients with PCP and CMV pneumonia fell in the left upper quadrant of the 2-axis model. Of 24 patients with suspected gastrointestinal CMV disease, 12 (50%) were classified as gastrointestinal CMV disease and the remaining 12 (50%) as bystander activation with no gastrointestinal CMV disease. The data for 11 of the 12 patients (92%) with gastrointestinal CMV disease were located in the left upper quadrant of the 2-axis model. Conclusions: Cases yielding low CMV IGRA results and high CMV viral replication appear to be true CMV infections. Further studies with large number of cases in different types of CMV disease should be proposed.
참고문헌 (20)
- Poornima Ramanan, "Cytomegalovirus Infections in Solid Organ Transplantation: A Review", Infection and Chemotherapy, 45(3), pp.260~271 (2013), 대한감염학회
- Egli A, "State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician", Clin Infect Dis, 55, pp.1678~1689 (2012)
- Moon SM, "Diagnostic yield of the cytomegalovirus (CMV) antigenemia assay and clinical features in solid organ transplant recipients and hematopoietic stem cell transplant recipients with CMV pneumonia", Transpl Infect Dis, 14, pp.192~197 (2012)
- Jang EY, "Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease", Clin Infect Dis, 48, pp.e121~e124 (2009)
- Park SY, "Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study", J Antimicrob Chemother, 67, pp.1486~1492 (2012)
- Park SY, "Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients:incidence, risk factors, and clinical outcomes", J Clin Microbiol, 49, pp.4179~4184 (2011)
- Millar AB, "Cytomegalovirus in the lungs of patients with AIDS: respiratory pathogen or passenger?", Am Rev Respir Dis, 141, pp.1474~1477 (1990)
- Dolin R., "Pneumocystitis Pneumonia", pp.637~658 (2008), Churchill Livingstone
- Miles PR, "Cytomegalovirus in the bronchoalveolar lavage fluid of patients with AIDS", Chest, 97, pp.1072~1076 (1990)
- Kim T, "Outcomes of non-HIV-infected patients with Pneumocystis pneumonia and concomitant pulmonary cytomegalovirus infection", Scand J Infect Dis, 44, pp.670~677 (2012)
- Galiatsatos P, "Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts", Dig Dis Sci, 50, pp.609~616 (2005)
- Roblin X, "Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis", Am J Gastroenterol, 106, pp.2001~2008 (2011)
- Matsuoka K, "Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients", Am J Gastroenterol, 102, pp.331~337 (2007)
- Lawlor G, "Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?", Inflamm Bowel Dis, 16, pp.1620~1627 (2010)
- Kornbluth A, "Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee", Am J Gastroenterol, 99, pp.1371~1385 (2004)
- Yoshino T, "Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies", Inflamm Bowel Dis, 13, pp.1516~1521 (2007)
- Bunde T, "Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells", J Exp Med, 201, pp.1031~1036 (2005)
- Malouli D, "Cytomegalovirus pp65 limits dissemination but is dispensable for persistence", J Clin Invest, 124, pp.1928~1944 (2014)
- Pipeling MR, "Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients", J Infect Dis, 204, pp.1663~1671 (2011)
- Bestard O, "Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation", Am J Transplant, 13, pp.1793~1805 (2013)